BioSpace News Archive

Taconic Biosciences, a global leader in providing drug discovery animal model solutions, and Biomodels, a provider of contract research services for preclinical drug development, have launched the Taconic-Biomodels Microbiome Initiative (TBMI), providing investigators with seamless access to complete germ-free and gnotobiotic microbiome study solutions, from design to data.

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, announced four poster presentations by key thought leaders Drs Boyer, Devries, Katz, and Pepose on APX3330 and Nyxol at the Association for Research in Vision and Ophthalmology Annual Meeting, which will take place in Denver, CO from May 1-4, 2022.

Medcura, Inc., a commercial-stage medical device company, announced the expansion of its senior management team to include Dr. Kenneth Renkens as its Chief Medical Officer.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive product candidates for pain management, CNS disorders and anti-viral indications, reported preclinical pharmacokinetics (PK) results for VRP324 (MET-CBD), a nose-to-brain delivery platform for CBD for the management of seizures in children and adults

Sunshine Biopharma, Inc. announced that it entered into a securities purchase agreement with certain institutional and accredited investors for aggregate gross proceeds of approximately $19.5 million, before deducting fees to the placement agent and other offering expenses payable by the Company.

Pharming Group N.V. announces that it has received a positive decision from the UK’s Medicines and Healthcare Products Regulatory Agency on a Paediatric Investigation Plan submission for leniolisib, an oral, selective phosphoinositide 3-kinase delta inhibitor, for the treatment of activated phosphoinositide 3-kinase delta syndrome in patients from 1 year of age to less than 18 years of age.

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announced that a complete data analysis of a randomized phase II study of bemcentinib in combination with standard of care therapy, ACCORD2, in hospitalized COVID-19 patients confirms that the primary efficacy endpoint was met.

DUBAI, United Arab Emirates, As per Future Market Insights, the global extraction kits market was valued at over US$ 1.15 Bn in 2021 and is expected to exhibit growth at a CAGR of 7.0% over the forecast period.

Albany NY, United States: The global body plethysmography market is projected to rise on the back of increasing need for precise and accurate diagnostic tools.

The healthcare packaging market is anticipated to grow extensively across the assessment period of 2020-2030.